• Molecular NameBupropion
  • SynonymAmfebutamone; Bupropion Hcl
  • Weight239.746
  • Drugbank_IDDB01156
  • ACS_NO34911-55-2
  • Show 2D model
  • LogP (experiment)3.741
  • LogP (predicted, AB/LogP v2.0)2.82
  • pka7.9
  • LogD (pH=7, predicted)1.12
  • Solubility (experiment)312 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-2.71
  • LogSw (predicted, AB/LogsW2.0)0.73
  • Sw (mg/ml) (predicted, ACD/Labs)0.2
  • No.of HBond Donors1
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds4
  • TPSA29.1
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn atypical antidepressant and smoking cessation aid. It acts as a strong norepinephrine and weak dopamine reuptake inhibitor, as well as α3β4-nicotinic receptor antagonist.
  • Absorption_value87.0
  • Absorption (description)Bupropion is well absorbed
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding80.0
  • Volume of distribution (VD)18.6 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic: important CYP2B6 and 2D6 involvement. Undergoes hepatic metabolism, via oxidation, hydroxylation and reduction. Peak plasma concentrations are reached within 3 h for sustained release preparations and 2 h for immediate release. Several metabolites are produced which are pharmacologically active. The three active metabolites are hydroxybupropion, the major metabolite, threohydrobupropion and erythrohydrobupropion.
  • Half life24 h
  • ExcretionMore than 60% of a dose is excreted in urine within 24 h, 87% over 96 h and 10% in faeces, with less than 1% being the parent drug. Bupropion crosses the placenta and is secreted in milk.
  • Urinary Excretion<1
  • Clerance36 ml/min/kg
  • ToxicitySymptoms of overdose include seizures, hallucinations, loss of consciousness, tachycardia, and cardiac arrest.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A